Search

More U.S. employers may trim GLP-1 coverage if claims keep rising this fast.

This is a useful signal for how large employers are responding to expensive new drug classes. If the trend spreads, it could reshape benefits design across U.S. companies and intensify the cost debate around GLP-1 coverage.

More U.S. employers will trim GLP-1 coverage as weight-loss drug claims keep climbing.

This is a bellwether for corporate benefits. If a brand as visible as Starbucks is trimming coverage, other employers may follow.